Investor · 1 deal
Sydney, NSW
Every published round Homart Pharmaceuticals took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Wellnex Life | Venture debt | Oct 2022 | $6.2m | Participant | Techboard, @AuManufacturing (24 Oct 2022), @AuManufacturing (6 Jun 2022) |
Companies Homart Pharmaceuticals has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Wellnex Life | Oct 2022, Venture debt | 1 | 0 |
Fund closes reported for Homart Pharmaceuticals, as distinct from the investments it has made.
Companies Homart Pharmaceuticals has backed that another company then bought. An exit for the holding, not a deal Homart Pharmaceuticals did.
Stories naming Homart Pharmaceuticals. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Roundup covering manufacturing placements by Sparc Technologies and Aurora Labs, Wellnex's planned London listing, an autonomous navy boat trial, a workplace fine, a software degree launch and AusBiotech's next CEO.
A manufacturing roundup covering a China milk powder supply deal, a methane emissions incentive, a nasal spray distribution agreement, a university space course, a government tax refund, and two companies' fresh capital raises.